Skip to main content
토론으로 돌아가기

제약 분야의 글로벌 혁신자로서의 중국의 부상(인센티브가 중요함)

Healthcare
글로벌
March 24, 2026에 시작됨

This paper examines China’s transition from pharmaceutical “free rider” to global innovator over the last decade. In 2010, China accounted for less than 8% of global clinical trials; by 2020, it had surpassed the US in annual registered clinical trial volume. To study this transformation, we compile a comprehensive, synchronized database spanning the pharmaceutical drug […] The post The rise of China as a global innovator in pharma (incentives matter) appeared first on Marginal REVOLUTION. Re...

출처 기사

진술 추가 분석 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
5 투표할 진술 • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 5/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM 게시자: will • Mar 24, 2026
중국의 제약 부문 성장은 눈에 띄지만, 의약품 개발의 윤리적 관행과 규제 감시에 대한 우려를 제기한다.
AI 번역 · 원문 보기

While China's growth in the pharma sector is notable, it raises concerns about ethical practices and regulatory oversight in drug development.

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: will • Mar 24, 2026
제약 혁신자로서 중국의 부상은 긍정적인 발전이며, 글로벌 경쟁을 강화하고 의약품 가격을 낮춘다.
AI 번역 · 원문 보기

China's rise as a pharmaceutical innovator is a positive development, as it enhances global competition and drives down drug prices.

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: will • Mar 24, 2026
중국으로의 임상시험 규모 변화는 세계화의 더 광범위한 추세를 반영하며, 제약 산업의 자연스러운 발전으로 봐야 한다.
AI 번역 · 원문 보기

The shift in clinical trial volume to China reflects broader trends in globalization and should be seen as a natural evolution in the pharma industry.

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: will • Mar 24, 2026
제약 분야의 중국의 빠른 발전은 지적재산권 도용의 위험을 초래하고 의약품 안전의 확립된 글로벌 기준을 훼손한다.
AI 번역 · 원문 보기

China's rapid advancement in pharma poses risks of intellectual property theft and undermines established global standards in drug safety.

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: will • Mar 24, 2026
제약 분야에서 글로벌 혁신자로의 중국의 전환은 전 세계 보건 성과를 개선할 수 있으며, 모든 인구에 이익을 줄 수 있다.
AI 번역 · 원문 보기

China's transition to a global innovator in pharmaceuticals could lead to better healthcare outcomes worldwide, benefiting populations everywhere.

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us